(株)ミズホメディーの貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証STD | 医薬品 | 4595/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2022/01/14 | 日証協 | 947,800株 | +9.86% | 394,964株 | -28.59% | 742,098株 | +1.79% | 156,216株 | +2.91% |
2022/01/07 | 日証協 | 862,700株 | -5.58% | 553,100株 | +30.73% | 729,018株 | -3.38% | 151,802株 | +5.8% |
2021/12/30 | 日証協 | 913,660株 | 0% | 423,100株 | 0% | 754,534株 | 0% | 143,481株 | 0% |
2021/12/24 | 日証協 | 913,660株 | -16.56% | 423,100株 | -58.32% | 754,534株 | -14.51% | 143,481株 | -31.68% |
2021/12/17 | 日証協 | 1,094,960株 | +22.8% | 1,015,232株 | +122.22% | 882,624株 | +13.16% | 210,013株 | +15.63% |
2021/12/10 | 日証協 | 891,660株 | -6.67% | 456,864株 | -23.52% | 780,011株 | +0.13% | 181,629株 | -13.72% |
2021/12/03 | 日証協 | 955,380株 | +34.24% | 597,380株 | +73.22% | 779,010株 | +23.22% | 210,501株 | +155.45% |
2021/11/26 | 日証協 | 711,700株 | -3.41% | 344,864株 | -27.99% | 632,214株 | -1.44% | 82,404株 | +9.53% |
2021/11/19 | 日証協 | 736,800株 | +0.4% | 478,900株 | -29.08% | 641,428株 | -0.45% | 75,231株 | -76.65% |
2021/11/05 | 日証協 | 527,500株 | +1.7% | 206,800株 | +13.19% | 484,002株 | +5.51% | 84,908株 | +9.13% |
2021/10/29 | 日証協 | 518,700株 | -13.01% | 182,700株 | -66.4% | 458,707株 | -5.87% | 77,805株 | -49.58% |
2021/10/22 | 日証協 | 596,300株 | +24.46% | 543,764株 | +1076.98% | 487,307株 | +17.28% | 154,306株 | +504.86% |
2021/10/15 | 日証協 | 479,100株 | -3.41% | 46,200株 | -66% | 415,512株 | -3.1% | 25,511株 | -38.99% |
2021/10/08 | 日証協 | 496,000株 | +11.21% | 135,900株 | +136.35% | 428,785株 | +5.64% | 41,816株 | +10.87% |
2021/10/01 | 日証協 | 446,000株 | +3.62% | 57,500株 | -50.39% | 405,885株 | +4.59% | 37,715株 | +27.83% |
2021/09/24 | 日証協 | 430,400株 | -12.75% | 115,900株 | -8.02% | 388,080株 | -14.06% | 29,505株 | -49.4% |
2021/09/17 | 日証協 | 493,300株 | +3.2% | 126,000株 | +58.09% | 451,580株 | -2.25% | 58,312株 | -57.9% |
2021/09/10 | 日証協 | 478,000株 | -6.4% | 79,700株 | +156.27% | 461,972株 | -2.31% | 138,505株 | +407.34% |
2021/09/03 | 日証協 | 510,700株 | -9.39% | 31,100株 | -92.03% | 472,873株 | -15.72% | 27,300株 | -86.03% |
※株式分割は考慮していませんのでご注意ください。
Page Top